Bomyntra (Denosumab-Bnht) Patent Expiration, LOE Window & CMS Spending
Bomyntra (Denosumab-Bnht) by Fresenius Kabi: Biologic BLA (PHS Act / Purple Book), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $3,346 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Fresenius Kabi |
| FDA Application & Pathway | B761398 (BLA) |
| Exclusivity / Cliff Horizon | Biologic BLA (PHS Act / Purple Book) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($3,346 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.